Hassan Kotey

Mr. Hassan Kotey

orcid

Research Focus & Metrics

Academic Career Length

3Years (2024-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 January 2024 in Advances in Pharmacological and Pharmaceutical Sciences
Verified
Journal Article
Open access
JDJulius T. Dongdem
Julius T. Dongdem
AEAxandrah E. Etornam
Axandrah E. Etornam
SBSolomon Beletaa
Solomon Beletaa
IAIssah Alidu
Issah Alidu
Hassan KoteyHassan Kotey
Hassan Kotey
CWCletus A. Wezena
Cletus A. Wezena
The discovery and characterization of the signal cascades of the β‐adrenergic receptors have made it possible to effectively target the receptors for drug development. β‐Adrenergic receptors are a class A rhodopsin type of G protein‐coupled receptors (GPCRs) that are stimulated mainly by catecholamines and therefore mediate diverse effects of the parasympathetic nervous system in eliciting “fight or flight” type responses. They are detectable in several human tissues where they control a plethora of physiological processes and therefore contribute to the pathogenesis of several disease conditions. Given the relevance of the β‐adrenergic receptor as a molecular target for many pathological conditions, this comprehensive review aims at providing an in‐depth exploration of the recent advancements in β3‐adrenergic receptor research. More importantly, we delve into the prospects of the β3‐adrenergic receptor as a therapeutic target across a variety of clinical domains.